Following a recent $61 Million Series B fundraise, the company announces significant platform optimizations to accelerate product adoption and growth among healthcare systems
LOS ANGELES, Oct. 16, 2024 /PRNewswire/ — Regard, the AI-powered clinical insights platform that empowers clinicians to unlock the full potential of patient data, announced today the release of multiple upgrades to its core clinical insights platform that will expand diagnostic coverage, improve accuracy, and ultimately, advance the industry standard for product quality. The enhancements come shortly after the company raised $61 Million in a Series B fundraise led by OAK HC/FT.
“Today’s upgrades underscore Regard’s unique approach to product innovation, and represent critical steps toward scaling our clinical insights platform to accomplish our mission of bringing world-class healthcare to everyone,” said Danny Tryon, Director of Product at Regard. “By investing in Regard’s robust intelligence infrastructure, we’re able to be more nimble and responsive to our customers’ evolving needs, reducing time on the backend and improving the industry standard for product quality.”
These platform enhancements include a first-of-its-kind, no-code diagnostic builder designed to significantly reduce the time and resources needed to develop and scale critical diagnoses, ultimately reducing the time to realize clinical insights that could impact patient care. It also enables Regard’s clinical staff to have an even deeper relationship with the diagnostic algorithms, and facilitates the delivery of higher quality of care. Additional upgrades will reduce unnecessary friction within the engineering process and better support data normalization, specifically enabling the platform to ingest and provide actionable insights from unstructured data.
This upgrade enables:
“The healthcare industry has seen a massive influx of AI technologies hitting the market over the past year, yet most are focused on adding more data into the EMR,” said Eli Ben-Joseph, co-founder and CEO of Regard. “While this is helpful, there needs to be a shift to focus on how AI can ensure doctors are leveraging the data in the EMR to provide the highest quality of care. This product expansion helps Regard do just that. We continue to prioritize how we normalize and translate critical data to support accurate clinical diagnostics and reduce data overload.”
Researchers at Boston’s Brigham and Women’s Hospital recently estimated that a harmful diagnostic error occurred in 1 in every 14 patients hospitalized, the majority of which were preventable. Regard’s platform helps eliminate these preventable errors by surfacing critical insights from an analysis of the EHR to clinicians, ensuring no critical information is missed. Since early 2024, the company has doubled the number of diagnoses its technology has surfaced to clinicians, bringing the total to over 4 million.
About Regard
Regard, the leading AI clinical insights platform, unlocks the full potential of patient data. Regard’s clinical intelligence layer drives the future of healthcare by augmenting clinical workflows and turning data into actionable insights. The technology helps health systems get the most value out of their clinical data: improving patient care, saving physicians time, and rejuvenating hospital finances. Regard is carving a path forward for health systems and physicians to meaningfully leverage AI, with the goal of empowering physicians to provide world-class healthcare to everyone.
Media contact:
Kara Spak
Kara@12080group.com
SOURCE Regard
HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…
This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…